I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 25 studies | 30% ± 12% | |
| CD16-negative, CD56-bright natural killer cell, human | 11 studies | 30% ± 9% | |
| CD16-positive, CD56-dim natural killer cell, human | 11 studies | 26% ± 9% | |
| plasmacytoid dendritic cell | 11 studies | 30% ± 8% | |
| CD4-positive, alpha-beta T cell | 8 studies | 28% ± 15% | |
| mucosal invariant T cell | 7 studies | 23% ± 6% | |
| mature NK T cell | 6 studies | 36% ± 17% | |
| gamma-delta T cell | 6 studies | 44% ± 14% | |
| innate lymphoid cell | 6 studies | 32% ± 12% | |
| naive thymus-derived CD4-positive, alpha-beta T cell | 5 studies | 21% ± 7% | |
| CD8-positive, alpha-beta T cell | 5 studies | 42% ± 11% | |
| group 3 innate lymphoid cell | 5 studies | 65% ± 12% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 4 studies | 25% ± 8% | |
| intraepithelial lymphocyte | 3 studies | 42% ± 14% | |
| T cell | 3 studies | 35% ± 10% |
